89bio Inc (ETNB) concluded trading on Thursday at a closing price of $9.62, with 4.55 million shares of worth about $43.76 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 19.80% during that period and on June 12, 2025 the price saw a loss of about -4.18%. Currently the company’s common shares owned by public are about 145.98M shares, out of which, 141.29M shares are available for trading.
Stock saw a price change of -3.41% in past 5 days and over the past one month there was a price change of 23.33%. Year-to-date (YTD), ETNB shares are showing a performance of 23.02% which increased to 13.58% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.16 but also hit the highest price of $11.84 during that period. The average intraday trading volume for 89bio Inc shares is 2.07 million. The stock is currently trading 1.27% above its 20-day simple moving average (SMA20), while that difference is up 21.20% for SMA50 and it goes to 15.66% higher than SMA200.
89bio Inc (NASDAQ: ETNB) currently have 145.98M outstanding shares and institutions hold larger chunk of about 106.18% of that.
The stock has a current market capitalization of $1.40B and its 3Y-monthly beta is at 1.53. It has posted earnings per share of -$3.38 in the same period. It has Quick Ratio of 18.03 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ETNB, volatility over the week remained 3.21% while standing at 4.85% over the month.
Analysts are in expectations that 89bio Inc (ETNB) stock would likely to be making an EPS of -0.48 in the current quarter, while forecast for next quarter EPS is -0.52 and it is -2.26 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.52 which is -0.4 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.48 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 40.34% while it is estimated to decrease by -6.54% in next year. EPS is likely to shrink at an annualized rate of 13.99% for next 5-years, compared to annual growth of 32.21% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on March 14, 2025 offering a Neutral rating for the stock and assigned a target price of $11 to it. Coverage by Citigroup stated 89bio Inc (ETNB) stock as a Buy in their note to investors on March 13, 2025, suggesting a price target of $25 for the stock. On February 04, 2025, Wolfe Research Initiated their recommendations, while on April 22, 2024, BofA Securities Resumed their ratings for the stock with a price target of $30. Stock get a Sector perform rating from RBC Capital Mkts on January 12, 2024.
